Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Rev Esp Enferm Dig ; 112(9): 712-715, 2020 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-32496109

RESUMO

AIM: to evaluate the safety and effectiveness of self-expandable metal stent placement for malignant gastric outlet obstruction (GOO). METHODS: a retrospective, analytic cohort study at a single, tertiary-care center. RESULTS: thirty-six patients that underwent stent placement for GOO of malignant origin were identified during the study period. Technical success was achieved in 36 (100 %) patients and clinical success was achieved in 31 patients (86.1 %). Before the procedure, 17 (54.8 %) patients had a gastric outlet obstruction score (GOOSS) of 0, which is a complete inability of oral intake. Twenty-three patients were alive 30 days after the procedure, two (8.6 %) patients had a GOOSS of 1, ten (43.3 %) had a GOOSS of 2 and eleven (47.9 %) had a GOOSS of 3. Abdominal pain was present in all 31 patients before the procedure and only seven (22.6 %) patients continued with abdominal pain 24 hours after the procedure. During follow-up, ten (30.3 %) patients developed complications related to the stents and none of them was fatal. Additional therapy due to partial occlusion of the stent was necessary in three patients. The stents functional duration had a median of 72 days (IQR 25-75 15-105 days) and was closely related to overall survival. CONCLUSION: palliative stenting for gastroduodenal obstruction is a safe, feasible and effective therapy to treat patients with malignant gastric outlet obstruction.


Assuntos
Obstrução da Saída Gástrica , Neoplasias Gástricas , Estudos de Coortes , Obstrução da Saída Gástrica/etiologia , Obstrução da Saída Gástrica/cirurgia , Humanos , Cuidados Paliativos , Estudos Retrospectivos , Stents , Resultado do Tratamento
2.
Int J Clin Rheumtol ; 7(6): 651-659, 2012 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-23525186

RESUMO

Sjögren's syndrome (SS) is a chronic inflammatory systemic autoimmune disease. The disease spectrum extends from sicca syndrome to systemic involvement and extraglandular manifestations, and SS may be associated with malignancies, especially non-Hodgkin's lymphoma. Patients with SS present a broad spectrum of serologic features. Certain serological findings are highly correlated with specific clinical features, and can be used as prognostic markers.

3.
Autoimmun Rev ; 9(4): 241-5, 2010 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-19879978

RESUMO

Bechet's disease (BD) is an inflammatory, multi systemic disease with spontaneous remissions and relapses similar to various autoimmune diseases. BD leads to organ damage, including the eyes, skin, joints, etc., which produces various clinical manifestations. The central histopathologic characteristic is systemic vasculitis with perivascular inflammatory infiltrates. The etiopathogenesis is unknown, although immunological abnormalities, possibly induced by susceptible microbiological pathogens, have been postulated.


Assuntos
Síndrome de Behçet/diagnóstico , Síndrome de Behçet/etiologia , Síndrome de Behçet/fisiopatologia , Corticosteroides/uso terapêutico , Síndrome de Behçet/tratamento farmacológico , Síndrome de Behçet/epidemiologia , Diagnóstico Diferencial , Eritema , Predisposição Genética para Doença , Antígenos HLA-B/genética , Antígeno HLA-B51 , Humanos , Oriente Médio , Peptidil Dipeptidase A/genética , Polimorfismo Genético , Protrombina/genética , Vasculite Sistêmica , Trombose , Fator de Necrose Tumoral alfa/genética , Úlcera
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA